Biopharmaceutical Process Analytical Technology Market

The global biopharmaceutical process analytical technology market is projected to reach USD 2.6 billion by 2029 from USD 1.2 billion in 2024, at a CAGR of 16.0% during the forecast period.

Government regulations ensuring drug safety, increased investments in research and development by biopharmaceutical companies, improvements in drug standards, growing governmental support in developing countries, and advancements in analytical device technology are the primary drivers of market expansion. However, the significant costs associated with implementing Process Analytical Technology (PAT) systems and a shortage of skilled personnel are expected to somewhat hinder market growth in the near future.

To know about the assumptions considered for the study download the pdf brochure

The biopharmaceutical process analytical technology market exhibits a competitive landscape, with numerous established and emerging players evenly distributing market shares. As of 2023, the key players operating in the global biopharmaceutical process analytical technology market are Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Mettler- Toledo International Inc. (US), Shimadzu Corporation (Japan), Waters Corporation (US), Emerson Electric Co. (US), Bruker Corporation (US), ABB Ltd. (Switzerland), PerkinElmer, Inc. (US), and Carl Zeiss AG (Germany), among others.

Thermo Fisher Scientific:

Thermo Fisher Scientific Inc. is introducing innovative solutions to address analytical challenges in diverse laboratory settings. With the launch of the Thermo Scientific Dionex Inuvion lori Chromatography (IC) system, the company aims to simplify and enhance ion analysis processes. This adaptable system offers easy reconfiguration, providing a comprehensive solution for precise determination of ionic and small polar compounds, ensuring dependable and consistent results. Furthermore, Thermo Fisher Scientific Inc. is broadening its strategic vision by unveiling a Raman spectroscopic analyzer, which revolutionizes process monitoring, particularly in biopharmaceutical manufacturing. This pioneering instrument allows non-invasive, continuous analysis without the need for sample preparation. With a rapid setup time of just 15 minutes, it swiftly delivers spectral data on desired analytes in seconds, facilitating efficient and seamless operation across various applications.

Agilent Technologies:

Agilent Technologies, Inc. employs a blend of organic and inorganic growth strategies to uphold its position in the global analytical technology sector. Their research and development endeavors prioritize exploring novel products and enhancements across various technological domains. Furthermore, the company places significant emphasis on forging strategic partnerships to bolster its manufacturing and innovation capabilities.

Recently, Agilent Technologies Inc. finalized the acquisition of Avida Biomed, an up-and-coming entity in the life sciences sector. Avida Biomed specializes in crafting advanced target enrichment workflows tailored for clinical researchers utilizing next-generation sequencing (NGS) methods, particularly in cancer research, with distinct expertise in this arena. For instance, in September 2022, Agilent collaborated with Mettler Toledo to pioneer a new sample preparation workflow for a chromatographic instrument. Additionally, in June 2022, Merck and Agilent Technologies united to propel forward a cutting-edge portfolio of process analytical technologies (PAT).

Water Corporation:

Waters Corporation has earned acclaim for its steadfast dedication to innovation, a cornerstone of its enduring brand identity. Through a continuous flow of groundbreaking products, Waters has solidified its leading position in the analytical technology market, significantly strengthening its market presence. Central to this success is a robust research and development (R&D) program, tirelessly focused on advancing and commercializing products that not only expand but also enhance and modernize its existing product lineup. Alongside its overarching commitment to innovation, Waters Corporation has demonstrated notable expertise in biopharmaceutical process analytical technology (PAT). Utilizing substantial R&D investments, Waters has made significant progress in developing state-of-the-art solutions tailored to meet the evolving demands of the biopharmaceutical sector. These advancements not only equip researchers and manufacturers with the tools necessary to optimize their processes but also contribute to the broader advancement of pharmaceutical science.

In recent years, Waters Corporation has allocated substantial R&D investments, with expenditures totaling USD 176 million in 2022, USD 168 million in 2021, and USD 141 million in 2020. This consistent investment underscores the company's unwavering commitment to innovation and its dedication to driving technological advancements that fuel both its own growth and the advancement of the industries it serves, including biopharmaceutical process analytical technology.

Related Reports:

Biopharmaceutical Process Analytical Technology Market by Technology (LC, GC, MS, qPCR, NGS, NMR, Raman, IR Spectroscopy), Product (Analyzer, Sensor, Software), Application (Vaccine, Biologics, CGT), and End User - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]